TriangleNCT00089076 · OUTCOME
Duration of Response (Phase 2)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- Not reported
- Unit
- Not reported
- Interval / dispersion
- Not reported
- Time frame
- From response to progression (up to 2 years)
What was measured
Duration of response will be calculated from the documentation of confirmed response until the date of progression in the subset of patients who respond.
Analysis population: No participants proceeded to Phase 2 for evaluation.
Groups in this outcome
MDX-010
Patients receive anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody (MDX-010) IV over 90 minutes on day 1. Treatment repeats every 28 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity.
| Group | Source count |
|---|---|
| MDX-010 | 0 |
Reported measurements
No numerical measurement classes were posted for this outcome. Missing is not zero.
Complete source fields
- denoms
- counts
- group Id
- OG000
- value
- 0
- units
- Participants
- description
- Duration of response will be calculated from the documentation of confirmed response until the date of progression in the subset of patients who respond.
- groups
- description
- Patients receive anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody (MDX-010) IV over 90 minutes on day 1. Treatment repeats every 28 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity.
- id
- OG000
- title
- MDX-010
- population Description
- No participants proceeded to Phase 2 for evaluation.
- reporting Status
- POSTED
- time Frame
- From response to progression (up to 2 years)
- title
- Duration of Response (Phase 2)
- type
- SECONDARY
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice